References - Neonatal Intensive Care Drug Manual

|
Neonatal Intensive Care Drug Manual
|
bet | 293/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
References
|
Bravo MC, Cabanas F, Riera J, Perez-Fernandez E, Quero J, Perez-Rodriguez J, Pellicer A. Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. J Matern Fetal Neonatal Med. 2014;27:904-9.
Weiss H, Cooper B, Brook M, Schlueter M, Clyman R. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr. 1995;127:466-71.
Olgun H, Ceviz N, Kartal I, Caner I, Karacan M, Tastekin A, Becit N. Repeated Courses of Oral Ibuprofen in Premature Infants with Patent Ductus Arteriosus: Efficacy and Safety. Pediatr Neonatol. 2017;58:29-35.
Marconi E, Bettiol A, Ambrosio G, Perduca V, Vannacci A, Troiani S, Dani C, Mugelli A, Lucenteforte E. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies. Pharmacological Research. 2019;148 (no pagination).
Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews. 2019;2019 (6) (no pagination).
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews. 2018;2018 (9) (no pagination).
Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. The Cochrane database of systematic reviews. 2018;4:CD010061.
ElHassan NO, Bird TM, King AJ, Ambadwar PB, Jaquiss RD, Kaiser JR, Robbins JM. Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants. J Neonatal Perinatal Med. 2014;7:229-35.
Diot C, Kibleur Y, Desfrere L. Effect of ibuprofen on bilirubin-albumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus. Early human development. 2010;86:315-7.
Desfrere L, Thibaut C, Kibleur Y, Barbier A, Bordarier C, Moriette G. Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants. The Journal of pediatrics. 2012;160:258-64 e1.
Schneider DJ. The patent ductus arteriosus in term infants, children, and adults. Semin Perinatol. 2012;36:146-53.
Takami T, Yoda H, Kawakami T, Yamamura H, Nakanishi T, Nakazawa M, Takei Y, Miyajima T, Hoshika A. Usefulness of indomethacin for patent ductus arteriosus in full-term infants. Pediatr Cardiol. 2007;28:46-50.
Takami T, Yoda H, Ishida T, Morichi S, Kondo A, Sunohara D, Hoshika A, Kawakami T. Effects of indomethacin on patent ductus arteriosus in neonates with genetic disorders and/or congenital anomalies. Am J Perinatol. 2013;30:551-6.
Clyman RI, Couto J, Murphy GM. Patent Ductus Arteriosus: Are Current Neonatal Treatment Options Better or Worse Than No Treatment at All? Seminars in Perinatology. 2012;36:123-9.
Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117:1113-21.
Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants > 1000 grams. American journal of perinatology. 2008;25:661-6.
Reller MD, Rice MJ, McDonald RW. Review of studies evaluating ductal patency in the premature infant. Journal of Pediatrics. 1993;122:S59-S62.
Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL, Trial of Indomethacin Prophylaxis in Preterms I. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. The New England journal of medicine. 2001;344:1966-72.
Van Overmeire B, Van De Broek H, Van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics. 2001;138:205-11.
Dani C, Mosca F, Cresi F, Lago P, Lista G, Laforgia N, Del Vecchio A, Corvaglia L, Paolillo P, Trevisanuto D, Capasso L, Fanos V, Maffei G, Boni L. Patent ductus arteriosus in preterm infants born at 23-24 weeks' gestation: Should we pay more attention? Early human development. 2019;135:16-22.
Kalani M, Shariat M, Khalesi N, Farahani Z, Ahmadi S. A comparison of early ibuprofen and indomethacin administration to prevent intraventricular hemorrhage among preterm infants. Acta Medica Iranica. 2016;54:788-92.
Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, Zea AM, Zhang Y, Sadeghirad B, Thabane L. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants a systematic review and meta-analysis. JAMA - Journal of the American Medical Association. 2018;319:1221-38.
Lago P, Salvadori S, Opocher F, Ricato S, Chiandetti L, Frigo AC. Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants. Neonatology. 2014;105:46-54.
Dani C, Vangi V, Bertini G, Pratesi S, Lori I, Favelli F, Ciuti R, Bandinelli A, Martano C, Murru P, Messner H, Schena F, Mosca F. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clinical pharmacology and therapeutics. 2012;91:590-6.
Pourarian S, Takmil F, Cheriki S, Amoozgar H. The Effect of Oral High-dose Ibuprofen on Patent Ductus Arteriosus Closure in Preterm Infants. American journal of perinatology. 2015.
Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, Schepens P, Urien S. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. British journal of clinical pharmacology. 2008;65:629-36.
Barzilay B, Youngster I, Batash D, Keidar R, Baram S, Goldman M, Berkovitch M, Heyman E. Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. Archives of disease in childhood Fetal and neonatal edition. 2012;97:F116-9.
Yurttutan S, Erdeve O, Oncel MY, Ozdemir R, Dilmen U. The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen. The journal of maternal-fetal & neonatal medicine 2013;26:1306-10.
Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2009;22 Suppl 3:88-91.
Benitz WE, Committee on F, Newborn AAoP. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016;137.
Pedea (Ibuprofen). Australian Product Information. Accessed on 28 November 2019.
Product Information: Caldolor intravenous, injection, ibuprofen arginine injection. Cumberland Phamaceuticals Inc., Nashville, TN, 2014.
Product Information: Neoprofen intravenous, injection, ibuprofen lysine injection. Recordati rare diseases, Lebanon, NJ, 2013.
Ibuprofen arginine, Ibuprofen lysine. In: IV index. Trissel's 2 clinical pharmaceutics database (parenteral compatibility). Greenwood Village, Colorado: Truven Health Analytics. Accessed 11/9/1515.
Australian Injectable Drugs Handbook, 6th Edition, Society of Hospital Pharmacists of Australia 2014.
Micromedex solutions. Accessed on 30 January 2020.
|
Original version Date: 27/10/2015
|
Author: NeoMed Consensus Group
|
Current Version number: 1.2
|
Current Version Date: 24/9/2019
|
Risk Rating: Medium
|
Due for Review: 24/9/2022
|
Approval by: DTC
|
Approval Date:22/11/2019
|
|
| |